Peanut allergy patch offers hope for kids

NCT ID NCT05424731

AVAILABLE Disease control Sponsor: DBV Technologies Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program provides continued access to the Viaskin Peanut skin patch for children aged 2 and older with peanut allergy who previously completed a DBV712 study. The patch delivers a small amount of peanut protein through the skin each day to help desensitize the immune system. The goal is to reduce the risk of severe allergic reactions from accidental peanut exposure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Viaskin Peanut (DBV712) skin patch
What this could lead to: If successful, this program could help children with peanut allergy tolerate small amounts of peanut, reducing the risk of severe reactions from accidental exposure.
What could go wrong: This is an expanded access program, not a formal trial, so results are limited. The patch may cause skin irritation, and it does not cure the allergy—ongoing use is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEANUT ALLERGY

Contacts and locations

Locations

Early Access Care, LLC
AVAILABLE

Madison, Connecticut, 06443, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.